Canaccord analyst Kyle Mikson raised the firm’s price target on Veracyte (VCYT) to $43 from $40 and keeps a Hold rating on the shares. The firm said the company demonstrated strong execution in 3Q25, although they remain on the sidelines until they gain visibility to and confidence in long-term growth drivers.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte price target raised to $48 from $42 at UBS
- Veracyte’s Strong Financial Performance and Promising Pipeline Justify Buy Rating
- Veracyte’s Strong Financial Performance and Growth Prospects Justify Buy Rating and Increased Price Target
- Veracyte Reports Strong Q3 2025 Financial Performance
- Veracyte reports Q3 adjusted EPS 51c, consensus 32c